These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35139270)

  • 1. A New Way to Contain Unaffordable Medication Costs - Exercising the Government's Existing Rights.
    Engelberg AB; Avorn J; Kesselheim AS
    N Engl J Med; 2022 Mar; 386(12):1104-1106. PubMed ID: 35139270
    [No Abstract]   [Full Text] [Related]  

  • 2. Legal Challenges to State Drug Pricing Laws.
    Lee TT; Kesselheim AS; Kapczynski A
    JAMA; 2018 Mar; 319(9):865-866. PubMed ID: 29435585
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmaceuticals and medical devices: cost savings. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
    [No Abstract]   [Full Text] [Related]  

  • 4. Rx: higher prices.
    Kosterlitz J
    Natl J (Wash); 1993 Feb; 25(7):396-9. PubMed ID: 10125572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 6. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
    Sarpatwari A; Avorn J; Kesselheim AS
    JAMA; 2018 Jun; 319(23):2373-2374. PubMed ID: 29800027
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmaceuticals and medical devices: business practices. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
    [No Abstract]   [Full Text] [Related]  

  • 8. Lowering the cost of prescription drugs.
    Jindal B
    J La State Med Soc; 2003; 155(1):51. PubMed ID: 12656276
    [No Abstract]   [Full Text] [Related]  

  • 9. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. States sue generic drug makers for alleged price fixing.
    McCarthy M
    BMJ; 2016 Dec; 355():i6764. PubMed ID: 27993771
    [No Abstract]   [Full Text] [Related]  

  • 11. Balancing innovation, access, and profits--market exclusivity for biologics.
    Engelberg AB; Kesselheim AS; Avorn J
    N Engl J Med; 2009 Nov; 361(20):1917-9. PubMed ID: 19828525
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmaceuticals and medical devices: cost savings.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403843
    [No Abstract]   [Full Text] [Related]  

  • 13. The FTC v. Actavis roadmap: a guide to properly applying the rule of reason standard in reverse payment cases.
    Sharkey N
    J Leg Med; 2014; 35(3):445-66. PubMed ID: 25207633
    [No Abstract]   [Full Text] [Related]  

  • 14. Brazil and USA at loggerheads over production of generic antiretrovirals.
    Ahmad K
    Lancet; 2001 Feb; 357(9254):453. PubMed ID: 11273079
    [No Abstract]   [Full Text] [Related]  

  • 15. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
    Brockmeier MS
    Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564
    [No Abstract]   [Full Text] [Related]  

  • 16. The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs.
    Gudiksen KL; King JS
    J Leg Med; 2019; 39(2):95-120. PubMed ID: 31503534
    [No Abstract]   [Full Text] [Related]  

  • 17. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 18. Generics still unable to resolve ANDA patent issues by declaratory judgment, but is a supreme court resolution on the way?
    Eccleston LE
    Health Care Law Mon; 2006 Dec; ():3-5. PubMed ID: 17236678
    [No Abstract]   [Full Text] [Related]  

  • 19. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 20. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.